Contracting a non-COVID lower respiratory tract infection raises the risk of death 2 to 7 times over the next month to a year ...

The S&P 500 and the Dow Jones Industrial Average ended higher on Monday, as the benchmarks temporarily shook off the uncertainty around the Trump administration's upcoming tariff plans which had ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

Shares of Moderna and other vaccine makers dropped Monday after the Food and Drug Administration's vaccine chief, Peter Marks, said he would resign, citing conflicts with Health and Human Services ...

Eastern time, the S&P 500 was down 0.8 per cent, the Dow Jones Industrial Average was down 0.3 per cent, and the Nasdaq ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center ...

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official, Peter ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Investing.com -- Moderna (NASDAQ: MRNA) shares dropped 13% pre-open on Monday as investors reacted to the weekend news that the U.S. Food and Drug Administration’s (FDA) top vaccine official, Dr.

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...